Axxcess Wealth Management LLC Raises Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Axxcess Wealth Management LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 17.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,486 shares of the medical instruments supplier’s stock after acquiring an additional 1,270 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $2,069,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Becton, Dickinson and Company by 3,191.7% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 93,024 shares of the medical instruments supplier’s stock valued at $22,682,000 after buying an additional 90,198 shares during the period. SouthState Corp raised its holdings in Becton, Dickinson and Company by 1.0% during the fourth quarter. SouthState Corp now owns 7,341 shares of the medical instruments supplier’s stock worth $1,790,000 after purchasing an additional 72 shares during the last quarter. Running Oak Capital LLC raised its holdings in Becton, Dickinson and Company by 21.8% during the fourth quarter. Running Oak Capital LLC now owns 32,275 shares of the medical instruments supplier’s stock worth $7,870,000 after purchasing an additional 5,775 shares during the last quarter. Silver Lake Advisory LLC raised its holdings in Becton, Dickinson and Company by 2.3% during the fourth quarter. Silver Lake Advisory LLC now owns 21,251 shares of the medical instruments supplier’s stock worth $5,182,000 after purchasing an additional 485 shares during the last quarter. Finally, Wilbanks Smith & Thomas Asset Management LLC increased its position in Becton, Dickinson and Company by 4.0% during the fourth quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 3,976 shares of the medical instruments supplier’s stock worth $969,000 after buying an additional 152 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Barclays lifted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock traded down $5.67 on Friday, reaching $234.68. 1,722,353 shares of the company were exchanged, compared to its average volume of 1,291,373. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41. The company’s 50-day moving average is $238.45 and its two-hundred day moving average is $240.53. The firm has a market cap of $67.80 billion, a price-to-earnings ratio of 51.69, a P/E/G ratio of 1.93 and a beta of 0.45. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the firm earned $2.86 EPS. The firm’s revenue was up 4.6% compared to the same quarter last year. As a group, research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.